Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Lipocine Inc LPCN

Healthcare Biotechnology
Lipocine Inc. is a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral delivery to develop differentiated products for Central Nervous System (CNS) disorders. Its clinical development candidates include: LPCN 1154, oral brexanolone, for treatment of postpartum depression, LPCN 2101 for epilepsy, LPCN 2203 for essential tremor... see more

Recent & Breaking News (NDAQ:LPCN)

Lipocine to Present at the 27th Annual ROTH Conference

GlobeNewswire March 4, 2015

Lipocine Announces Presentation of LPCN 1021 Clinical Data at ENDO 2015

GlobeNewswire February 27, 2015

Lipocine to Present at the Cowen and Company 35th Annual Health Care Conference

GlobeNewswire February 24, 2015

Lipocine Announces Presentation of LPCN 1107 Clinical Data at the Society for Maternal-Fetal Medicine 35th Annual Meeting

GlobeNewswire January 30, 2015

Lipocine Inc. (Nasdaq: LPCN) to Ring The Nasdaq Stock Market Closing Bell

GlobeNewswire January 16, 2015

Lipocine Announces Positive Phase 1b Top-Line Results With LPCN 1107 in Pregnant Women

GlobeNewswire January 12, 2015

FDA Confirms Lipocine's Previously-Agreed Clinical Development Plan for LPCN 1021

GlobeNewswire December 15, 2014

Lipocine to Present at the Piper Jaffray 26th Annual Healthcare Conference

GlobeNewswire November 25, 2014

Lipocine Announces Management Changes

GlobeNewswire November 17, 2014

Lipocine Announces Financial and Operational Results for the Third Quarter of 2014

GlobeNewswire November 10, 2014

Lipocine Announces Positive Top-Line Results in Phase 2a Study of LPCN 1111

GlobeNewswire October 13, 2014

IPOs and Transactions Week in Review: September 29 - October 3

PR Newswire October 6, 2014

Lipocine Announces Positive Top-Line Results in Its Phase 3 Study of LPCN 1021 for Oral Testosterone Replacement Therapy

GlobeNewswire September 24, 2014

Lipocine to Host Conference Call and Webcast to Discuss Top-Line Results From the Phase 3 Study of LPCN 1021

GlobeNewswire September 23, 2014

Lipocine Announces First Patient Dosed in Phase 1 Study in Pregnant Women of LPCN 1107, Potentially the First Oral Product for the Prevention of Preterm Birth

GlobeNewswire September 8, 2014

Lipocine Announces Financial and Operational Results for the Second Quarter of 2014

GlobeNewswire August 13, 2014

Lipocine Announces Issuance of U.S. Patent for LPCN 1021

GlobeNewswire July 15, 2014

Lipocine Added to Russell Microcap Index

GlobeNewswire June 30, 2014

Lipocine to Present at the Jefferies 2014 Global Healthcare Conference

GlobeNewswire May 29, 2014

Lipocine Announces First Patient Dosed in Phase 2a Study of LPCN 1111, a Novel Testosterone Ester for Oral Testosterone Replacement Therapy

GlobeNewswire May 27, 2014